LRI Investments LLC Purchases 413 Shares of Natera, Inc. $NTRA

LRI Investments LLC increased its position in Natera, Inc. (NASDAQ:NTRA) by 469.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 501 shares of the medical research company’s stock after purchasing an additional 413 shares during the period. LRI Investments LLC’s holdings in Natera were worth $85,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. HighPoint Advisor Group LLC grew its stake in Natera by 30.8% in the first quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company’s stock worth $308,000 after purchasing an additional 468 shares during the period. Park Avenue Securities LLC purchased a new stake in Natera in the second quarter worth $1,525,000. Amalgamated Bank grew its stake in Natera by 9.8% in the first quarter. Amalgamated Bank now owns 8,293 shares of the medical research company’s stock worth $1,173,000 after purchasing an additional 740 shares during the period. Comerica Bank grew its stake in Natera by 24.1% in the first quarter. Comerica Bank now owns 141,106 shares of the medical research company’s stock worth $19,954,000 after purchasing an additional 27,379 shares during the period. Finally, GAMMA Investing LLC grew its stake in Natera by 32.3% in the first quarter. GAMMA Investing LLC now owns 848 shares of the medical research company’s stock worth $120,000 after purchasing an additional 207 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on NTRA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research note on Wednesday, October 8th. Royal Bank Of Canada set a $268.00 price objective on Natera and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Evercore ISI raised Natera to a “strong-buy” rating and set a $170.00 price objective for the company in a research report on Monday, July 28th. Stephens reaffirmed an “overweight” rating and set a $183.00 price objective on shares of Natera in a research report on Friday, August 15th. Finally, Wells Fargo & Company started coverage on Natera in a research report on Monday, September 22nd. They set an “equal weight” rating and a $175.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $192.88.

Insider Buying and Selling at Natera

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $159.99, for a total transaction of $479,970.00. Following the sale, the insider directly owned 117,559 shares in the company, valued at approximately $18,808,264.41. This trade represents a 2.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Michael Burkes Brophy sold 2,491 shares of the firm’s stock in a transaction on Tuesday, September 30th. The stock was sold at an average price of $162.05, for a total value of $403,666.55. Following the completion of the transaction, the chief financial officer owned 69,189 shares in the company, valued at approximately $11,212,077.45. This trade represents a 3.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 72,464 shares of company stock worth $10,963,125. Insiders own 5.63% of the company’s stock.

Natera Trading Up 2.9%

Shares of NTRA opened at $174.17 on Tuesday. The business’s fifty day simple moving average is $165.33 and its two-hundred day simple moving average is $157.54. Natera, Inc. has a 12 month low of $117.27 and a 12 month high of $183.00. The company has a market cap of $23.90 billion, a price-to-earnings ratio of -91.19 and a beta of 1.74.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business had revenue of $546.60 million for the quarter, compared to analysts’ expectations of $476.84 million. During the same quarter in the prior year, the business posted ($0.30) earnings per share. The business’s revenue for the quarter was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.